ArticleScientific reports2026
SLC27A1 overexpression correlates with lactylation and poor colorectal cancer progression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
SLC27A1 (solute carrier family 27 member 1), which encodes fatty acid transport protein 1 (FATP1), has been implicated in the development and progression of various cancers. However, its role in colorectal cancer (CRC) remains to be fully elucidated. This study combined a series of bioinformatics analyses and biological experiments to characterize the comprehensive function of SLC27A1 in CRC. The expression of SLC27A1 in CRC was analyzed using multiple databases. Bioinformatics methods were employed to explore the associations between SLC27A1 expression levels in CRC and its clinical significance, as well as immune infiltration. The function and potential mechanism of SLC27A1 in CRC were investigated through Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, gene set enrichment analysis (GSEA), and in vitro experiments. SLC27A1 was significantly upregulated in CRC. Its high expression correlated with adverse clinicopathological features and poor prognosis in CRC patients. SLC27A1 expression was closely linked to immune cell infiltration in CRC. GSEA analysis revealed that SLC27A1 is involved in multiple tumor-associated signaling pathways and negatively correlates with the tricarboxylic acid cycle and pyruvate metabolism. In vitro experiments demonstrated that SLC27A1 knockdown inhibited CRC cell proliferation and migration. In contrast, SLC27A1 overexpression promoted glucose uptake and lactate accumulation in CRC cells. Further analysis showed that SLC27A1 was significantly associated with multiple lactylation-related genes. The results of this study demonstrate that high expression of SLC27A1 is closely associated with poor prognosis, protein lactylation, and immune cell infiltration in CRC. Knockdown of SLC27A1 can suppress the proliferation and migration abilities of CRC cells. Therefore, SLC27A1 may serve as a promising independent prognostic biomarker and a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.